Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06934382 · ClinicalTrials.gov registry record · Phase 1
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
A Phase 1 study of T-Cell Acute Lymphoblastic Leukemia/Lymphoma, sponsored by Stephan Grupp MD PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT06934382 is a Phase 1 study of T-Cell Acute Lymphoblastic Leukemia/Lymphoma that is actively recruiting participants, run by Stephan Grupp MD PhD. The registered enrollment target is 33 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06934382, a Phase 1 study of T-Cell Acute Lymphoblastic Leukemia/Lymphoma, is actively recruiting participants, sponsored by Stephan Grupp MD PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
Conditions Studied
Interventions
- BIOLOGICAL Allogeneic anti-CD7 CAR-T cells (BEAM-201)
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2031-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06934382
The ClinicalTrials.gov registry entry for NCT06934382 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stephan Grupp MD PhD, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with T-Cell Acute Lymphoblastic Leukemia/Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Allogeneic anti-CD7 CAR-T cells (BEAM-201) is the first listed.
NCT06934382 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06934382 about?
NCT06934382 is a clinical study titled "Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma". This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
What is the current status of trial NCT06934382?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2025-04-29. Estimated completion is 2031-05-30.
What conditions does trial NCT06934382 study?
This clinical trial studies the following conditions: T-Cell Acute Lymphoblastic Leukemia/Lymphoma.
What interventions are being tested in trial NCT06934382?
The interventions under investigation include: Allogeneic anti-CD7 CAR-T cells (BEAM-201) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06934382?
This trial is sponsored by Stephan Grupp MD PhD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06934382 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.